feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Weight-Loss Jabs Linked to Severe Pancreatitis Risk

Weight-Loss Jabs Linked to Severe Pancreatitis Risk

30 Jan

•

Summary

  • UK regulators updated guidance due to increased pancreatitis reports.
  • Over 1.6 million adults used GLP-1 weight-loss jabs in England, Wales, Scotland.
  • MHRA identified 1,143 pancreatitis reports, including 17 fatalities.
Weight-Loss Jabs Linked to Severe Pancreatitis Risk

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has updated its guidance concerning GLP-1 weight-loss medications, such as semaglutide and tirzepatide. This action follows an observed rise in reports of severe acute pancreatitis associated with these drugs.

Between early 2024 and early 2025, approximately 1.6 million adults across England, Wales, and Scotland utilized these GLP-1 medications for weight loss. Pancreatitis is listed as an "uncommon" side effect in patient information leaflets, affecting about one in 100 individuals.

As of the most recent data, the MHRA's yellow card scheme has logged 1,143 reports of acute and chronic pancreatitis among users of semaglutide and tirzepatide, with 17 reported fatalities. A significant majority of these reports, 973, were logged in 2025. This update emphasizes the importance of patient and healthcare professional awareness of potential symptoms like severe, persistent stomach pain.

trending

Ohio snow emergency declared

trending

TikTok down in United States

trending

Andreeva matches Venus Williams' feat

trending

Warrington Hospital baby death

trending

Alexander Zverev advances in Australia

trending

Oilers host Capitals

trending

London celebrates Chinese New Year

trending

Liza Minnelli defends AI use

In parallel, the MHRA is collaborating on the Yellow Card Biobank study to investigate potential genetic links to pancreatitis risk. This research aims to identify individuals most susceptible to adverse reactions, enabling more personalized prescription strategies. Manufacturers like Novo Nordisk reiterate their commitment to patient safety and recommend strict medical supervision.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The MHRA updated its guidance to inform patients and healthcare professionals about the small risk of severe acute pancreatitis associated with GLP-1 weight-loss medications.
The MHRA's yellow card scheme has received 1,143 reports of acute and chronic pancreatitis from patients taking semaglutide and tirzepatide, with 17 reported fatalities.
Patients should be alert for symptoms such as severe, persistent stomach pain that may radiate to the back, and may be accompanied by nausea and vomiting.

Read more news on

Healthside-arrow

You may also like

Knock-off Weight Drugs: Deadly Risks Exposed

2 hours ago • 3 reads

article image

Generic Wegovy Approval Sparks Indian Race

23 Jan • 49 reads

article image

Obesity Pill: Cheaper, Needle-Free Future for UK?

15 Jan • 91 reads

article image

Millions of Australians May Soon Access Subsidized Wegovy

12 Jan • 112 reads

article image

New Wegovy Pill Offers Injectable Efficacy in Daily Dose

5 Jan • 224 reads

article image